Accelerate Diagnostics (NASDAQ:AXDX) Upgraded by BTIG Research to Strong-Buy Rating

Accelerate Diagnostics (NASDAQ:AXDX) was upgraded by investment analysts at BTIG Research to a “strong-buy” rating in a research note issued on Wednesday,Zacks.com reports.

Separately, StockNews.com started coverage on shares of Accelerate Diagnostics in a research note on Wednesday. They set a “hold” rating for the company.

Accelerate Diagnostics Stock Up 2.3 %

Shares of AXDX stock opened at $1.35 on Wednesday. Accelerate Diagnostics has a 12 month low of $0.73 and a 12 month high of $4.99. The firm has a market cap of $33.81 million, a PE ratio of -0.47 and a beta of 0.56. The stock has a 50 day moving average of $1.77 and a 200-day moving average of $1.55.

Insider Activity at Accelerate Diagnostics

In other Accelerate Diagnostics news, Director John Patience purchased 200,000 shares of the stock in a transaction on Tuesday, December 3rd. The shares were purchased at an average price of $1.57 per share, with a total value of $314,000.00. Following the acquisition, the director now directly owns 653,224 shares of the company’s stock, valued at $1,025,561.68. This represents a 44.13 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 43.60% of the company’s stock.

Institutional Trading of Accelerate Diagnostics

A hedge fund recently bought a new stake in Accelerate Diagnostics stock. Y Intercept Hong Kong Ltd purchased a new stake in Accelerate Diagnostics, Inc. (NASDAQ:AXDX) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 19,866 shares of the medical research company’s stock, valued at approximately $34,000. Y Intercept Hong Kong Ltd owned 0.08% of Accelerate Diagnostics at the end of the most recent reporting period. Hedge funds and other institutional investors own 17.14% of the company’s stock.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.